@article{d80ece4b3969470d845d45e8aaf65119,
title = "The association between handedness and clinicodemographic characteristics in people with multiple sclerosis: a brief report",
abstract = "A relationship between handedness and clinicodemographic profiles of people with multiple sclerosis was sought using data from the Multiple Sclerosis Partners Advancing Technology Health Solutions network of 10 multiple sclerosis centers in the USA and Europe. Handedness data were available for 8888 multiple sclerosis patients, of which 917 (10.3%) were left-handed. Clinicodemographic profiles of right versus left-handed multiple sclerosis patients were similar except for a slightly increased proportion of men who were left-handed, and slightly reduced performance on the manual dexterity test using the non-dominant hand in left-handed patients. We found no evidence to suggest a prognostic implica-tion of handedness in multiple sclerosis.",
keywords = "epidemiology, handedness, Multiple sclerosis",
author = "{for the Multiple Sclerosis Partners Advancing Technology Health Solutions Investigators} and Afsaneh Shirani and Cross, {Anne H.} and Naismith, {Robert T.}",
note = "Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) database was funded by Biogen..We would like to express our thanks to the MS PATHS clinical research coordinators at Washington University in St. Louis including Courtney Dula, MS, Dana Perantie, MPH, and Shannon Sides, BA, as well as all the other MS PATHS research coordinators at other sites. We would also like to thank Dana Perantie, MPH for her help with IRB preparation and submission. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) database was funded by Biogen.. Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AS is funded through a clinician scientist development award from the National Multiple Sclerosis Society (USA), and a clinical research training scholarship from the American Academy of Neurology. AHC has been a paid consultant for Biogen, Celgene, EMD-Serono, Genzyme, Genentech, and Novartis. AHC was funded in part by the Manny and Rosalyn Rosenthal – Dr John L Trotter MS Center Chair in Neuroimmunology of Barnes-Jewish Hospital Foundation. RTN has received honoraria for consulting for Alkermes, Biogen, Celgene, Novartis; and for speaking for EMD Serono, Genzyme, Genentech, and Novartis. Publisher Copyright: {\textcopyright} 2019, SAGE Publications Inc.. All rights reserved.",
year = "2019",
doi = "10.1177/2055217319832031",
language = "English (US)",
volume = "5",
journal = "Multiple Sclerosis Journal - Experimental, Translational and Clinical",
issn = "2055-2173",
publisher = "SAGE Publications Inc.",
number = "1",
}